Abbott's Pinaverium Bromide Tablets Recommended for Priority Review in China
Abbott
Diagnostic and pharmaceutical product manufacturers
▎WuXiEdited by Kant Content Team
According to the announcement on the official website of the Center for Drug Evaluation (CDE) on July 8, a pinaverium bromide tablet submitted by Abbott has been proposed for inclusion in the priority review channel, with the indication being:Symptomatic treatment of pain, abnormal bowel movements, and gastrointestinal discomfort associated with intestinal dysfunction; symptomatic treatment of pain associated with biliary dysfunction; preparation for barium enema.
This itemPublic information does not disclose the acceptance number。Reasons for Proposed InclusionFor:According to the priority review scope "(6) National MedicinesThe scenarios of "other priority review and approval stipulated by the Supervision and Administration Bureau" are included in the priority review and approval process.
Pinaverium Bromide Tablets(Pinaverium Bromide Tablets) is aDrugs for the treatment of functional gastrointestinal disorders. It serves asCalcium Channel Blockers, which helps restore the normal contraction process of the intestines. Public information shows,Pinaverium BromideEarliestIn 1975By Solvay Pharmaceuticals (now under Abbott)First Registration. In China,Registered by AbbottPinaverium Bromide Tablets(Product Name:Duspatal) was first approved for marketing in 2015, followed by multiple registration records. Meanwhile, since 2013 in China, severalGeneric Pinaverium Bromide Tablets Approved for Marketing in China.
This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Feel free to share it on your personal social media feed. For authorization to repost or other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
